ING has added $5m to a series B round for the natural language processing technology provider through a strategic partnership deal.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The immunotherapy developer, which counts Pfizer, Sanofi, Merck & Co, Eli Lilly, Amgen and Vertex Pharmaceuticals as early investors, has picked up $102m.

Personalised finance management service Albert secured $50m in a CapitalG-led round that included fellow corporate venturing vehicle American Express Ventures.

The antibody-based drug developer has now raised $210m altogether, with both SK Holdings and Legend Capital backing its series B-plus round.

Humanised antibody-based drug developer Harbour BioMed has now raised $210m altogether following a series B-plus round featuring Zhejiang University Future Capital.

The TV and social media-focused talent agency received $25.7m from ByteDance and has formed a strategic partnership with the coprorate.

Existing investor Sinopharm Capital came back for a $57.7m round that will support the progression of the small-molecule drug developer's pipeline.

VC fund 01 Advisors chipped in $14.5m to extend the corporate-backed IT management software provider's latest round to $39.5m.

Expense management software provider Fenbeitong has closed a series B-plus round co-led by Fidelity's Eight Roads firm, pushing its total funding to more than $58m.